Relugolix usage and dosage

Relugolix is a prescription drug used to treat adults with advanced prostate cancer. Patients started treatment with repagliflozin at a loading dose of 360 mg on the first day and continued oral treatment at a dose of 120 mg once daily. Regaglic can be taken with or without food. If treatment with regaglic is interrupted for more than 7 days, restart regaglic at a loading dose of 360 mg on the first day and continue at a dose of 120 mg once daily.

For prostate cancer patients receivingGnRH receptor agonists and antagonists, treatment is usually continued when non-metastatic or metastatic castration-resistant prostate cancer develops. Avoid coadministration of repagliflozin with oral P-gp inhibitors. If coadministration cannot be avoided, repagliflozin should be taken first and separated by at least 6 hours between doses. If short-term treatment with a P-gp inhibitor is necessary, treatment with Repaglica may be interrupted for up to two weeks. Avoid coadministration of repagliflozin with concomitant P-gp and strong CYP3A inducers. If unavoidable, increase the dose of repagliflozin to 240 mg once daily; after discontinuation of combined P-gp and strong CYP3A inducers, resume the recommended dose of repagliflozin at 120 mg once daily.

The original drug of Regogliflox has not yet been launched in the country, so it is not covered by medical insurance. There are European and Japanese versions of the original drug Rleglik available overseas. The ingredients of the two are basically the same. The price of the European version of 120mg*30 tablets per box may be around RMB 4,000, and the price of the Japanese version of 40mg*100 tablets per box may be around RMB 4,000 (the price may fluctuate due to exchange rates). Currently, there are no generic versions of Repagliflox produced and put on the market.